DHA Test · Blood

If you eat fish regularly, take omega-3 supplements, or do neither, this test tells you what actually ended up in your blood. DHA (docosahexaenoic acid) is the primary omega-3 fat in your brain and heart tissue, and your circulating level reflects months of dietary intake, not just last night's salmon. A large pooled analysis across multiple prospective studies found that people with higher blood DHA levels had significantly lower rates of death from heart disease, cancer, and all other causes combined.

What makes this measurement valuable is that you cannot guess your level from diet alone. Absorption varies by genetics, body weight, supplement formulation, and what you eat alongside your omega-3 source. Two people taking the same fish oil capsule can end up with very different blood levels. Testing is the only way to know where you stand.

What DHA Does in Your Body

DHA is the most abundant omega-3 fat in your brain and the light-sensing cells of your retina (the layer at the back of your eye). It sits in cell membranes (the thin outer walls that surround every cell), where it keeps those membranes flexible and responsive. This flexibility matters because it affects how well your cells send signals, respond to hormones, and manage inflammation.

Your body can make small amounts of DHA from plant-based omega-3s (like those in flaxseed), but the conversion rate is very low. For practical purposes, your DHA status depends on how much you get from seafood or supplements. Once DHA reaches your brain, it is stored in the fatty outer layer of brain cells and released to produce molecules that help brain cells survive, form new connections, and calm down inflammation.

Heart Disease and Mortality

The connection between blood DHA and cardiovascular outcomes is among the best-studied in nutrition science. A meta-analysis of prospective studies reported that people in the highest category of circulating DHA had a significantly lower risk of dying from cardiovascular disease, cancer, or any cause compared to those in the lowest category. The relationship held across different populations and blood measurement methods.

A dose-response meta-analysis of omega-3 intervention trials found that higher doses of EPA plus DHA (the two main marine omega-3s) produced greater reductions in heart attack and coronary heart disease events. In statin-treated patients with coronary artery disease, maintaining a plasma omega-3 level of at least 4% (EPA plus DHA as a share of total fatty acids) prevented progression of arterial plaque in non-diabetics, while patients below that threshold showed more plaque growth.

One complexity worth understanding: some observational data suggest that when both EPA (eicosapentaenoic acid, the other major marine omega-3) and DHA are measured together, very high DHA may blunt the protective association seen with higher EPA. This does not mean DHA is harmful. It means the two omega-3s may have partly different effects on heart risk, and measuring them separately (as this test does) gives you more precise information than a combined number alone.

Type 2 Diabetes Risk

A pooled analysis of 20 prospective cohort studies found that higher blood levels of marine-derived omega-3s, including DHA, were associated with a lower risk of developing type 2 diabetes. This association was specific to the seafood-derived omega-3s (EPA, DPA, and DHA), not to plant-based ALA (alpha-linolenic acid). If you are tracking metabolic health, your DHA level adds information that fasting glucose and HbA1c do not capture.

Brain Health and Cognitive Aging

DHA makes up a large fraction of the fat in your brain, so it is not surprising that low levels show up in studies of cognitive decline. In a randomized trial of 485 healthy older adults with age-related memory complaints, 900 mg per day of DHA for 24 weeks improved performance on learning and memory tests compared to placebo. A meta-analysis confirmed that DHA plus EPA supplementation at doses above 1 gram per day improved a specific type of memory called episodic memory (the ability to recall events and experiences) in adults with mild memory complaints.

The timing matters, though. In a trial of 402 people with established mild to moderate Alzheimer's disease, 2 grams per day of DHA for 18 months did not slow cognitive or functional decline. The pattern across studies suggests DHA may help protect the brain before significant damage occurs, but cannot reverse disease once it is established. A review of DHA and Alzheimer's disease stage concluded that supplementation may be most effective in people who carry the APOE4 gene variant (a known Alzheimer's risk factor) and are treated before dementia symptoms develop.

If your DHA level is low and you are concerned about long-term brain health, especially if you have a family history of dementia or carry APOE4, this is information you can act on early.

Pregnancy and Early Development

DHA is essential for fetal brain and eye development. In a randomized trial of 1,150 pregnant women, taking 1,000 mg of DHA per day (compared to 200 mg per day) reduced the rate of early preterm birth, particularly in women whose baseline DHA levels were low. A separate trial of 301 pregnancies found that prenatal DHA at 600 mg per day reduced early preterm birth and improved infant visual attention, though no consistent cognitive advantages persisted through age six.

One caution for very preterm infants: a meta-analysis found that giving DHA directly to very preterm babies (with or without the omega-6 fat ARA) did not protect against major complications and may have increased the risk of a lung condition called bronchopulmonary dysplasia. This is a specialized neonatal concern, not relevant to adult testing, but it illustrates that more is not always better in every context.

Cancer Associations

Higher circulating DHA has been linked to lower cancer mortality in the same large pooled analysis that showed cardiovascular and all-cause mortality benefits. A genetic analysis technique called Mendelian randomization, which uses inherited gene variants to estimate cause-and-effect relationships, studied over 264,000 European individuals and found that genetically predicted higher plasma DHA was associated with lower ovarian cancer risk, particularly for a subtype that affects the lining of the ovaries (endometrioid ovarian cancer). In breast cancer, a small randomized trial of high-dose DHA (4.4 g per day) during chemotherapy found no improvement in tumor markers or survival outcomes, though the supplement was safe and well tolerated.

EPA vs. DHA: Do They Do Different Things?

Your body handles EPA and DHA differently, and their effects on blood lipids are not identical. A systematic review of head-to-head trials found that DHA has a slightly greater effect on lowering triglycerides (blood fats), raising the protective HDL-2 cholesterol fraction, and lowering heart rate and blood pressure. Both EPA and DHA reduce inflammation and inflammatory gene activity. However, DHA tends to modestly raise LDL cholesterol (the "bad" cholesterol), while EPA does not.

Large cardiovascular outcome trials using EPA alone (at prescription doses) have shown clear reductions in heart attacks and cardiovascular death. Trials using mixed EPA plus DHA have shown smaller or inconsistent benefits on hard endpoints, despite similar triglyceride lowering. This difference is still being studied, but it means knowing your DHA level separately from your EPA level gives you a clearer picture of your omega-3 profile and how your body may respond to different supplement strategies.

Reference Ranges

Most published clinical thresholds are for the Omega-3 Index, which combines EPA and DHA in red blood cell membranes and reports them as a percentage of total fatty acids. DHA-specific cutpoints are less standardized but are emerging from population studies. The ranges below are drawn from a global survey and US population data. Your lab may use a different assay or report results in different units, so always compare your results within the same lab over time.

A large US population study found that over 95% of American children and 68% of adults had combined EPA plus DHA serum levels below the threshold roughly equivalent to Dietary Guidelines recommendations. The Omega-3 Index target of 8% to 11% is the range most consistently linked to lower risk of fatal heart disease, lower total mortality, and better brain function across multiple research groups. Getting from a typical US baseline of 3% to 5% up to that target usually requires sustained supplementation or regular fatty fish intake for at least 12 weeks.

When Results Can Be Misleading

DHA measured in red blood cell membranes reflects your average intake over the past two to three months (roughly the lifespan of a red blood cell). This makes it more stable than a single-day plasma measurement, but a few factors can still distort your reading.

• Body weight: Larger individuals may need higher omega-3 doses to reach the same blood level as smaller individuals. Two people taking identical supplements can have meaningfully different results based on body composition alone.
• Supplement formulation: DHA in triglyceride or phospholipid form (a fat naturally found in cell walls) is absorbed better than the ethyl ester form found in some cheaper supplements. Taking omega-3s with a meal containing fat also improves absorption. A low result might reflect poor absorption rather than low intake.
• Acute illness or inflammation: Chronic inflammatory conditions and acute illness can alter fatty acid distribution in the blood. If you are recovering from a significant illness, consider retesting once you have been well for several weeks.
• Statin therapy: Statins may change how omega-3 levels relate to other lipid markers without clearly shifting the DHA number itself. If you are on a statin, your DHA level is still meaningful, but interpreting it alongside your full lipid panel requires awareness of this interaction.

Tracking Your Trend

A single DHA measurement gives you a useful snapshot, but tracking over time is where the real value lies. If you start a new supplement, change your diet, or switch formulations, you need a follow-up test to see whether the change actually moved your number. Red blood cell omega-3 levels take 8 to 12 weeks to fully reflect a new intake pattern, so retesting sooner than that can underestimate the effect.

A practical cadence: get a baseline test, make your dietary or supplement changes, then retest in three to four months. If your level has reached your target range, retest annually to make sure it stays there. If it has not moved enough, you may need a higher dose, a different formulation, or to take your supplement with a fattier meal. Dose-response data show that DHA-focused regimens at 1,000 mg per day or more for at least 12 weeks generally push the Omega-3 Index (a related but combined EPA plus DHA measure) from typical US baselines into the 8% or higher range.

What to Do With an Abnormal Result

If your DHA is low, the first step is straightforward: increase your marine omega-3 intake through diet, supplements, or both, then retest in three to four months to confirm the change took effect. If your level remains stubbornly low despite adequate intake, consider whether your supplement form (ethyl ester vs. triglyceride), timing (with or without food), or body weight may be limiting absorption.

A low DHA alongside elevated triglycerides, high hs-CRP (a marker of inflammation), or borderline blood sugar results paints a picture of broader metabolic and cardiovascular risk that deserves attention. In that scenario, order or review your full lipid panel including ApoB, check your fasting insulin or HOMA-IR (a measure of insulin resistance), and consider an Omega-3 Index test if your lab reports DHA alone. If triglycerides are above 500 mg/dL, prescription-strength omega-3 therapy (typically 4 grams per day) is a guideline-supported treatment your clinician can prescribe.

If you are interested in brain health specifically, pair your DHA result with cognitive baseline testing and, if available, APOE genotyping. A low DHA in someone carrying APOE4 with a family history of Alzheimer's is a finding worth acting on aggressively with supplementation and monitoring, given evidence that DHA may be most protective before cognitive symptoms appear.